Get the Stockscreener App
144.00
1.05%
-1.575
Icon Plc stock is traded at $144.00, with a volume of 292.28K.
It is down -1.05% in the last 24 hours and down -2.04% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$145.58
Open:
$146.7
24h Volume:
292.28K
Relative Volume:
0.20
Market Cap:
$11.63B
Revenue:
$8.19B
Net Income/Loss:
$758.19M
P/E Ratio:
15.69
EPS:
9.18
Net Cash Flow:
$1.06B
1W Performance:
-4.31%
1M Performance:
-2.04%
6M Performance:
-28.86%
1Y Performance:
-58.39%
1-Day Range:
$143.22
$148.83
1-Week Range:
$143.22
$155.90
52-Week Range:
$125.10
$345.86
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
144.05 | 12.05B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
417.15 | 160.88B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
192.38 | 143.62B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
518.00 | 43.33B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.04 | 34.37B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
157.05 | 28.45B | 15.50B | 1.33B | 2.16B | 7.34 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
ICON Dominates Phase 1 Clinical Trials: Outperforms All Major CROs in 17 Key Metrics - Stock Titan
Do You Believe in the Upside Potential of ICON PLC (ICLR)? - Insider Monkey
Clinical Trial Investigative Site Network Market Top Players - openPR.com
Launch Your Career as a Life Science Intern at ICON, Apply Now! - BioTecNika
Icon (ICLR) Gets a Buy from Leerink Partners - The Globe and Mail
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $187 - 富途牛牛
ICON plc stock price target lowered to $187 at Truist Securities - Investing.com Nigeria
ICON plc stock price target lowered to $187 at Truist Securities By Investing.com - Investing.com South Africa
WCM Investment Management, LLC Significantly Reduces Stake in Icon PLC - GuruFocus
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability - 01net
Should You Hold ICON PLC (ICLR)? - MSN
Will ICON PLC (ICLR) Benefit from R&D Spending? - Insider Monkey
ICON plc Schedules Q2 2025 Earnings Call - TipRanks
ICON plc Schedules Second Quarter 2025 Earnings Conference Call - Business Wire
ICON plc Reports Strong Interim Financial Results for Early 2025 - TipRanks
Medical Device Regulatory Affairs Market Top PlayersICON, - openPR.com
ICON plc Announces 2025 AGM and Key Resolutions - TipRanks
Icon PLC (ICLR) Shares Up 3.47% on Jun 6 - GuruFocus
Regulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - GlobeNewswire Inc.
ICON Public Limited (NASDAQ:ICLR) Short Interest Up 25.4% in May - Defense World
Icon PLC (ICLR) Stock Price Up 4.49% on Jun 4 - GuruFocus
ICON at William Blair Conference: Strategic Focus Amid Challenges - Investing.com
ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review - mx.advfn.com
Here's Why You Should Retain ICLR Stock in Your Portfolio Now - TradingView
Icon PLC (ICLR) Down 9.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
ICON plc to Present at the William Blair 45th Annual Growth Stoc - GuruFocus
ICON plc to Present at Annual Growth Stock Conference By Investing.com - Investing.com South Africa
ICLR December 2026 Options Begin Trading - Nasdaq
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference - BioSpace
ICON plc to Present at Annual Growth Stock Conference - Investing.com
ICON plc to Present at William Blair Growth Stock Conference - TipRanks
ICON’s SWOT analysis: cro stock faces headwinds amid potential rebound - Investing.com
ICON Life Science Internship For BSc & MSc – Applications Closing Soon! Hurry! - BioTecNika
Redburn Atlantic Adjusts Icon (ICLR) Price Target Amid Market Uncertainty | ICLR Stock News - GuruFocus
ICON Plc stock hits 52-week low at $127.51 amid market challenges By Investing.com - Investing.com South Africa
ICON Plc stock hits 52-week low at $127.51 amid market challenges - Investing.com Nigeria
ICON releases its ICON Cares 2024 Report | ICLR Stock News - GuruFocus
ICON releases its ICON Cares 2024 Report - Silicon Canals
ICON Releases ICON Cares 2024 Report Highlighting ESG Achievements - TipRanks
ICON Leads CRO Industry in Sustainability: Achieves 70% GHG Reduction and TIME Recognition - Stock Titan
ICON holds lead as most active CRO, GlobalData finds - The Pharma Letter
Icon (ICLR) Maintains Outperform Rating Amid Price Target Adjustment | ICLR Stock News - GuruFocus
Icon (ICLR) Price Target Reduced by Mizuho to $173 | ICLR Stock News - GuruFocus
Daily Progress: Icon Plc (ICLR) Drop -5.54, Closing at 135.10 - DWinneX
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):